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This paper forms part of a series of recommendations on
measurements of catalytic concentrations oJenzymes. Others deal
with:
Part 1. General conditions [1].
(Approved 1979.)
Part 2. Methodfor aspartate aminotransferase [2].
(Approved 1985.,)
Part 3. Methodfor alanine aminotransferase [3].
(Approved 1985.)
Part 4. Methodfor y-glutamyltransferase [4].
Part 5. Methodfor alkaline phosphatase [5].
Part 6. Reference materials for enzyme measurements.
(Stage 1, draft 1989- copy available from Committee
Chairman.)
1. Introduction
The principles applied in the selection ofthe conditions of
measurement are those stated in previous publications by
this expert panel [1]. Human serum and tissue extracts
have been used as the sources of enzymes. The final
concentrations of substrates, auxiliary and indicator
enzymes have been selected on the basis of experimental
evidence and data in the literature dealing with the three
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dimeric forms of creatine kinase in serum. The method is
also suited for the determination of creatine kinase
variants which may be present in serum.
2. Principle
Creatine kinase (ATP: creatine N-phosphotransferase,
EC 2.7.3.2, CK) catalyses the reversible N- phosphoryl-
ation of creatine by the Mg2+-ATP complex [6, 7]. Clear
distinctions should be made between cytosolic and
mitochondrial forms, as well as between tissue and serum
forms. This document is primarily concerned with the
cytosolic enzymes, although information relating to other
forms is given.
The dimeric molecule consists of two elongated polypep-
tide subunits termed ’B’ and ’M’. The two subunits are
very similar. Each has a relative molecular mass of 41
300-43 000 [8, 9] and contains one catalytic site and one
reactive sulphhydryl group [10].
The nomenclature of the subunits is based on the tissue
source oftwo of the dimeric CK isoenzymes: ’B’ for brain
and ’M’ for muscle. Different cytosolic isoenzymes occur
in different tissues [11]. The homologous dimer,
CK-MM, predominates in muscle tissue. The hybrid
isoenzyme, CK-MB is found in developing skeletal and
fully developed cardiac muscle. It also occurs in trace
amounts in adult skeletal muscle. The cytosolic CK
isoenzymes can also be named on the basis of their
electrophoretic mobility towards the anode [12].
Isoenzymes BB, MB and MM of creatine kinase are
named CK- 1, CK-2 and CK-3, respectively. A fourthCK
isoenzyme occurs in mitochondria ofmyocardium, skele-
tal muscle, brain and liver tissues, and is thought to be
composed of a third type of subunit [13, 14].
Mitochondrial CK isolated from human heart, skeletal
muscle, brain, and liver are isolated as macromolecular
complexes 15-17].
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In human serum, CK may be present in various forms:
CK-MM may occur in several forms of which MM1,
MM2 and MM3 are the best documented [18].
CK-MB.
CK-BB.
Macro CK Type 1: immunoglobulin-linked isoenzyme
forms (predominantly IgG-linked CK-BB 19-21 ].
Macro CK Type 2: probably a serum form of
mitochondrial CK, although conclusive evidence is still
lacking 16, 21, 22].
There are no reports of a dimeric mitochondrial CK in
serum.
In order to ensure full catalytic activity, the creatine
kinase molecule in serum must be reactivated by a
reducing sulphhydryl compound.
Table 1. IFCC conditionsfor measurement of creatine kinase.
Creatine phosphate 30 mmol/1
Adenosine-5’-diphosphate (ADP) 2 mmol/1
Imidazole 100 ml/1
Ethylenediaminetetraacetic acid 2 mmol/1
(EDTA)
Mg
2/ 10 mmol/1
N-acetyl-L-cysteine 20 mmol/1
Adenosine-5’-monophosphate
(AMP) 5 mmol/1
P1,p5-Di(adenosine-5’-)penta- 10 btmol/1
phosphate
D-Glucose 20 mmol/1
Nicotinamide adenine dinucleotide 2 mmol/1
phosphate (NADP/)
Hexokinase (E.C. 2.7.1.1) from yeast 50 btkat/l (3000 U/l)
Glucose-6-phosphate dehydrogenase 33 btkat/1 (2000 U/l)
(E.C. 1.1.1.49) from yeast
Reaction temperature 30"0 _+ 0"05C
pH (30 C) 6.60 +_ 0.05
Volume fraction of serum 0"0435 (1:23)
Different kinetic properties have been found for each of
the human creatine kinase isoenzymes, including those of
human origin [23-25]. Kinetic data have also been
compiled for mitochondrial CK [26]. Therefore,
measurement of total creatine kinase in serum requires
using an assay system whose reaction conditions are a
compromise.
The proposed method for the measurement of the
catalytic concentration of creatine kinase in serum is
based on the principles proposed by Oliver [27] and later
modified by Rosalki [28] and Szasz et al. in a series of
publications [23, 29-34]. Recommended or standard
methods published by professional societies in the United
Kingdom [35], FR Germany [36], The Netherlands [37],
France [38], Scandinavia [39, 40] and Switzerland [41]
are also based on these publications and have also been
considered.
The primary reaction (1), catalysed by creatine kinase,
and the coupled reactions (2) and (3) are:
Creatine phosphate + ADP Creatinekinase_>
EC 2.7.3.2
Creatine + ATP (1)
Note: The concentrations apply to the complete reaction
mixture. The catalytic concentrations of hexokinase and
D-glucose-6-phosphate dehydrogenase must be determined as
described in Appendix B.
3. IFCC conditions for measurement
The reaction conditions have been chosen on the basis of
univariate and multivariate experiments with sera from
healthy individuals, sera from patients with acute myo-
cardial infarction, sera from patients with skeletal muscle
diseases, and with isolated human isoenzymes [30, 38--40,
43, 44].
These IFCC conditions are optimized reaction con-
ditions, which are defined 1] as those conditions that are
most favourable for both the kinetic reactions and the
technical aspects of the measurement, i.e. these con-
ditions do not necessarily provide maximum activity.
The reaction is initiated by creatine phosphate.
Following an initial lag phase, substrate conversion
proceeds linearly with time and amount of enzyme until
deceleration occurs due to build-up ofinhibitingNADPH
and decreased NADP+ concentration (see table 1).
Hexokinase ATP + D-Glucose
EC 2.7.1.1
ADP + D-Glucose-6-phosphate (2)
D-Glucose-6-phosphate + NADP+
Glucose-6-phosphate-dehydrogenase D-Glucono-5-1actone-
EC 1.1.1.49
6-phosphate + NADPH + H
/ (3)
The equilibrium in (1) favours the formation of creatine
and ATP at pH values around 6-7, due to the higher
energy of creatine phosphate as compared to that ofATP
and the lower Km values for ADP and creatine phosphate
than for ATP and creatine [42]. This primary reaction is
coupled through the auxiliary reaction (2), catalysed by
hexokinase, to the NADPH forming indicator reaction
(3) catalysed by glucose-6-phosphate dehydrogenase.
4. Instrumentation and equipment
A thermostatted spectrometer suitable for accurate
measurement at 339 nm should be used.
The specifications for the equipment (for example,
spectral band width, light path, accuracy of thermostats)
should meet those of previous recommendations [1].
Instruments must be capable of monitoring the linear
portion of the rate ofconversion curve and should display
both the initial absorbance of the reaction mixture and
absorbance versus time during the measurement interval.
The temperature of the reaction mixture in the cuvette
must be controlled at 30"0 _+ 0"05 C.
All volumetric glassware used for the preparation of
reagents and for pipetting must meet US National
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Institute of Standards and Technology (NIST) Class A
specifications, American Chemical Society Micro-
chemical specifications (tolerance is 0"997 to 1"003) or
other national equivalents, pH meters must be calibrated
at 30 1"0 C by use of a standardized reference buffer
(for example, NIST) with a pH value within unit of the
reaction measurement pH.]"
be prepared in calibrated flasks with water meeting the
following standards [45]:
Electrical resistivity: ->2"0 x 104 ohm/m at 25 C.
pH: 6"0-7"0.
Silicates: <0"1 mg/l.
5. Reagents
(1) Imidazole (CaH4N2), Mr 68" 1.
(2) Creatine phosphate, disodium salt, tetrahydrate
(CaHsNO5PNa2"4HO), Mr 327"2.
(3) Magnesium acetate (CHaOMg’4HO), Mr
214"5.
(4) D-Glucose (C6H1206), Mr 180.2.
(5) Ethylenediaminetetraacetic acid, disodium salt,
dihydrate [EDTA] C10HlaOsN2Na’2H20), Mr
372.2.
(6) Adenosine-5’-monophosphate, disodium salt,
hexahydrate [AMP] (CIoHINsOyPNa’6HO),
Mr 499.2.
(7) Adenosine-5’-diphosphate, monopotassium salt,
dihydrate [ADP] (CIoHIaN5OI0P2K’2HO), Mr
501"3.
(8) N-Acetyl-L-cysteine (CsHgNOaS), Mr 163"2.
(9) P1,ps-Di(adenosine-5’-)pentaphosphate, trilith-
ium salt (C20H6N100PsLia, Mr 934"2.
(10) [3-Nicotinamide adenine dinucleotide phosphate,
disodium salt [NADP] (C1H6NyOlyPNa), Mr
787.4.
(11) Hexokinase (EC 2.7.1.1) from yeast (lyophilized
or in glycerol).
(12) Glucose-6-phosphate dehydrogenase (EC
1.1.1.49) from yeast (lyophilized or in glycerol).
(13) Acetic acid (C:H40), Mr 60"1.
(14) Sodium hydroxide (NaOH), Mr 40"0.
(15) Sodium chloride (NaC1), Mr 58"45.
6. Purity of reagents
The assessment of reagent purity is made on the basis of
functional (performance ofreagent), chemical (analytical
evaluation) and instrumental (absorbance or fluor-
escence characteristics) tests. Further details are given in
Appendix B.
To prevent the growth of microorganisms in solutions,
sterilized containers should be used. All solutions should
]" NIST Standard Reference Materials, KH2PO4 (SRM 186-I-c) and
Na2HPO4 (SRM 186-II-c) can be used as a 25 mmol kg
-l solution
having a pH of6’851 at 30 C. The slope ofthe pH meter can be adjusted
with a solution containing KHPO4 (SRM 186-I-c) at 8’695 mmol kg
-1
and NaHPO4 (SRM 186-II-c) at 30"43 mmol kg-1, having a pH of
7"403 at 30 C.
7. Preparation of solutions
No. Reagent solution for measurement of CK catalytic
concentration
(I) Stock solution ofimidazole buffer.
(II) Stock solution of buffer-reagent mixture
(without N-acetyl-L-cysteine or enzymes).
(III) Working solution of buffer-reagent-enzyme
mixture.
(IV) Working solution of creatine phosphate
(initiating reagent).
(V) NaC1, 154 mmol/1 (diluting reagent).
No. Reagent solutionfor measurement ofauxiliary enzymes
see Appendix B
(VI) Working solution III with N-acetyl-L-cysteine
but without enzymes.
(VII) Glucose-6-phosphate dehydrogenase, stock
solution (approximately 4 mkat/1, diluted
101 fold.
(VIII) Solution VII, diluted 101 fold.
(IX) D-Glucose-6-phosphate (initiating reagent).
(X) Working solution III with N-acetyl-L-cysteine
and glucose-6-phosphate delaydrogenase
but without hexokinase.
(XI) Hexokinase, stock solution (approximately 4
mkat/1), diluted 101 fold.
(XII) Solution XI, diluted 101 fold.
(XIII) Adenosine-5’-triphosphate (initiating re-
agent).
(XIV) Gluconate-6-phosphate (initiating reagent).
(XV) Reagent III, diluted 5 times with solution VI.
(I) Stock solution of imidazole acetate buffer (imid-
azole 127"8 mmol/1, magnesium acetate 12"8
mmol/1, and EDTA 2"6 mmol/1, pH 7"3 at room
temperature).
Dissolve the following components in approxi-
mately 950 ml ofdeionized or distilled water, which
meets the above-mentioned requirements: imid-
azole 8"70 g; magnesium acetate tetrahydrate 2"74
g; and ethylenediaminetetraacetic acid, disodium
dihydrate 968 mg. Adjust the pH to 7"3 at room
temperature (20-26 C) with acetic acid, mol/1.
Add water to a final volume of exactly 1.
The absorbance ofthe buffer solution (I) at 339 nm
should be less than 0"050 [39].
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(II) Stock solution of buffer-reagent mixture (imid-
azole buffer 127"8 mmol/1, with EDTA 2"6 mmol/1,
magnesium acetate 12"8 mmol/1, ADP 2"6 mmol/1,
AMP 6"4 mmol/1, P1,p5-Di(adenosine-5’-)penta-
phosphate 12"8 tmol/1, D-glucose 25"6 mmol/1,
NADP+ 2"6 mmol/1, pH 7"10 to 7"15 at room
temperature).
Transfer 900 ml of stock imidazole acetate buffer
solution I to a 1500 ml beaker containing a
magnetic stirrer. Dissolve the following com-
ponents with stirring at room temperature:
Adenosine-5’-diphosphate, monopotassium salt,
dihydrate, 1303 mg.
Adenosine-5’-monophosphate, disodium salt,
hexahydrate, 3195 mg.
P1,p5-Di(adenosine-5’-)pentaphosphate, trilith-
ium salt, 12 mg.
D-glucose, 4613 mg.
NADP+, disodium salt 2012 mg.
Note: Use of adenine nucleotide salt prep-
arations other than those indicated may require
different substance amounts due to different Mr
values. Use of free acids will cause difficulty in
dissolution of the substances and may require
the addition of alkali.
(IV) Working solution ofcreatine phosphate, 345 mmol/
1. Dissolve 1129 mg of creatine phosphate, di-
sodium tetrahydrate in deionized water and bring
the volume to 10"0 ml with water.
Working solution IV should have an absorbance at
339 nm of less than 0"050 [39].
(V) Solution of sodium chloride, 154 mmol/1.
Dissolve 0"9 g of sodium chloride in 100 ml of
water.
8. Stability of solutions
Based on studies given in Nealon [39], the stabilities of
these solutions are"
Solution I 3 months at 4 C.
Solution II 2 months at -20 C.
Solution III: 5 days at 4 C, 24 hours at room
temperature, or 3 weeks at -20 C.
Solution IV: 3 months at 4C or 12 months at -20 C.
9. Specimen procurement, stability, transportation
and storage
Serum is the preferred specimen. Plasma should not be
used.
Transfer the solution to volumetric flask and add
stock imidazole acetate buffer solution I to a final
volume of exactly 1000 ml. Distribute 90 ml
aliquots of this stock solution into 100-ml bottles.
(III) Working solution of buffer-reagent-enzyme
mixture (imidazole 115"0 mmol/1, EDTA 2"3
mmol/1, magnesium acetate 11.5 mmol/1 EDTA
2"3 mmol/1, magnesium acetate 11"5 mmol/1, ADP
2"3 mmol/1, AMP 5"8 mmol/1, P1,ps-Di-
[adenosine-5’-]pentaphosphate 11"5 tmol/1, D-
glucose 23"0 mmol/1, NADP+ 2"3 mmol/1,
N-acetyl-L-cysteine 23"0 mmol/1, hexokinase 57"5
ukat/1 (3450 U/l), and glucose-6-phosphate de-
hydrogenase 38"2 tkat/1 (2300 U/l), with a pH of
6"6 at 30 C).
Bring 90 ml of stock solution II to room tempera-
ture. Dissolve 375 mg of N-acetyl-L-cysteine in
solution II. Adjust the pH, if necessary, to 6"6 at
30 C with acetic acid, 1.mol/1.
Add a volume of hexokinase from yeast containing
5"8 tkat (350 U) measured at 30C (see Appendix
B), in order to give a catalytic concentration of57"5
kat/1 (3450 U/l) in solution III. Add a volume of
glucose-6-phosphate dehydrogenase from yeast
containing 3"8 kat (230 U) measured at 30C (see
Appendix B) in order to give a catalytic concen-
tration of 38"0 tkat/1 (2300 U/l) in solution III.
Add water to a final volume of 100 ml.
The 339 nm absorbance of this solution should be
less than 0"200 [39].
Collect blood by venipuncture with minimal manipula-
tion and stasis. Avoid haemolysis to minimize interfer-
ence by erythrocyte adenylate kinase. Use blood-
collection tubes that contain no additives. Physical
exercise can increase the creatine kinase catalytic con-
centration in the blood [46].
Blood cells should be separated from serum with 2 hours
of venipuncture.
The stability of the CK isoenzymes varies. At pH 7"5,
complexes ofimmunoglobulins with CK-BB are the most
stable 16] followed by MM, mitochondrial CK, MB and
BB 17]. At pH 8"5, mitochondrialCK is more stable 16]
thanMM [21 ]. Isoenzyme stabilities, defined as less than
5% loss under the specified storage conditions [33, 47],
are:
CK-MM: room temperature, 48 h; 4 C, 2 weeks; -20
C, month [33].
CK-MB: room temperature, 2 h [33]; 4C, 5 days [47].
CK-BB: room temperature, 0"5 h [33]; 4C, day [47];
-20 C, 2 days [47]; -80 C, 4 days [47].
All isoenzymes are stable in the complete reaction
mixture for 30 min at room temperature and 10 min at
37 C.
Loss of catalytic concentration may be caused by (a)
thermal inactivation; (b) oxidation Of reactive thiol
groups; (c) increasing pH due to loss of CO2; and (d)
irradiation with light [48]. In addition, the temperature
of the fluid used to reconstitute lyophilized serum has
been reported to affect catalytic concentration [49].
25IFCC The measurement of the catalytic concentration of creatine kinase
Specimens should be transported and stored at low
temperatures in tightly-closed tubes with minimal air
space over the serum and should be protected from light.
The catalytic concentration stability is apparently pH
dependent, being maximal around pH 6"5 to 7"0 and
minimal around pH 8"0 to 8"5 [50, 51 ]. Stability may thus
vary somewht for individual sera in conditions of acidosis
or alkalosis and with the isoenzyme distribution.
Total CK catalytic concentration in serum from healthy
individuals is comprised largely ofCK-MM with 1-3% of
CK-MB [52]. In patients with acute myocardial infarc-
tion, CK-MB may be increased considerably and is,
therefore, of diagnostic usefulness [53]. CK-MB may be
elevated in patients with skeletal muscle damage due to
excessive exercise, intramuscular injections, surgical
operations, multiple trauma, cerebral arterial embolism,
convulsions, and malignant hyperthermia [54], and in
Duchenne muscular dystrophy and similar musculoskele-
tal diseases [55].
Elevated catalytic concentrations of CK-BB have been
observed in patients following surgical resection of the
prostate or of the GI tract, caesarean section and
craniotomy [56]. CK-BB has also been found in the
serum of patients with various types of cancer [57],
colonic infarction [58] and brain damage [59, 60].
10. Measurement
10.1. Measurement conditions
Wavelength: 339 (+_ nm).
Bandwidth: +2 nm.
Light path: 10"0 0"01 mm.
Final.volume of reaction mixture: 2"30 ml.
Temperature: 30"0 0"05 C (thermostatted cuvette
compartment).
10.2. Handling of solutions
Before pipetting, the temperature of reagent solutions
and of specimen must be brought to the calibration
temperature of the pipettes. However, use of other
temperatures results in a relative error of only 0"000025
for each C difference from the pipette calibration
temperature and for most situations this error is
negligible.
During the preincubation period, the solution in the
cuvettes must attain a temperature of 30"0 0"05 C
before initiating the reaction.
Table 2. Composition ofthe reaction mixturesfor determinations of
the rate of conversions required for creatine kinase rate
measurements.
Reagent Initiating
Kind of reaction Sample mixture reagent
(A) Overall
(B) Sample blank
(C) Reagent blank
Serum Solution III Solution IV
Serum Solution III Water
Solution V Solution III Solution IV
All measurements are made against a cuvette containing
reagent grade water.
Table 3. Analytical systemfor measurement ofthe overall creatine
kinase rate of conversion.
Pipette Substance or catalytic
into concentration in final,
cuvettes: Volume complete mixture
Solution
III
Serum
2"00 ml Imidazole
EDTA
Mg2+
ADP
AMP
p1 ,p5.D adenosine-5 ’-)-
pentaphosphate
N-acetyl-L-cysteine
D-glucose
NADP+
Hexokinase (3000 U/l)
Glucose-6-phosphate de-
hydrogenase (2000 U/l)
0" 100 ml Volume fraction
100 mmol/1
2 mmol/1
10 mmol/1
2 mmol/1
5 mmol/1
10 [mol/1
20 mmol/1
20 retool/1
2 mrnol/1
50 tkat/1
33 tkat/1
0.0435
(:)
Mix carefully, avoiding the loss of any volume of the mixture.
Incubate the reaction mixture at 30C and wait a minimum of
300 for full reactivation of creatine kinase and temperature
equilibration. Before the following step, solution IV should be at
30 C.
Solution
IV 0"200 ml Creatine phosphate 30 mmol/1
Mix again and wait 120 for the end of the lag phase. Monitor
the increase in absorbance at 339 nm as a function oftime, for at
least an additional time of 60 s.
The procedure for the overall reaction of the individual
measurement is described in table 3. The other two
measurements are performed identically by replacing the
sample or starting reagent as described in table 2.
10.3. Subprocedures that constitute one measurement
The overall reaction (A), catalysed by creatine kinase and
other enzymes, particularly adenylate kinase (EC
2.7.4.3), the sample blank reaction (B) and the reagent
blank reaction (C) comprise the individual measure-
ments for rate of conversion. Reaction (C) does not enter
directly into the calculation of results (see section 10"5),
see table 2.
10.4. Measurement interval
A lag phase of up to 120 s may occur. The values of A/s
(--a) of the overall creatine kinase reaction (A) are
constant over a period of at least 60 s following the lag
phase for sera with catalytic concentrations of creatine
kinase up to 40 tkat/1 (2400 U/l), provided that the
spectrometer is capable of making accurate absorbance
readings up to 2"000 A. If the change of absorbance is
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greater than 0"01/s the serum sample .must be diluted
with solution V. However, this will lead to inaccuracy due
to nonlinearity of the dilution curve (see Appendix A for
details).
10.5. Correctionsfor blank reactions
The rate of the overall reaction (A) is corrected for any
sample blank reaction (B) as follows:
a corrected aA aB.
The subscripts, A and B, indicate the composition of the
reaction mixtures referred to in table 2. The corrected
value of a is used in the following calculations. It equals
the true rate of conversion catalysed by creatine kinase.
The reagent blank rate of conversion, C, does not enter
into the calculations, but is used to ascertain the quality
of the reagents. Its value should be less than a change in
absorbance of0"0007 per 60 s. If it is higher, the purity of
the reagents must be reassessed (see Appendix B).
Table 4. Imprecision ofCK method.
Catalytic
concentrations
(tkat/1)
Coefficients of variations
Within-day Day-to-day
0’59 0.023 0"027
2"69 0"009 0"013
5.81 0.008 0"010
For measurement at 339 nm, with sufficiently sensitive
spectrometers, the limit of detectability using 180 s
monitoring after the end of the lag phase is 24 +_ 8 nkat/1
(1.4 + 0.5 U/1 [38].
The analytical sensitivity has been established to be an
increase in absorbance at 339 nm of 0"001 per 60 s, but
will depend on the instrument used.
13. Reference ranges
11. Calculation
The catalytic concentration, b, of creatine kinase in the
sample is calculated as follows"
V
e.l.v
Reference ranges have not yet been determined for this
method. However, reference values are available for
many of the national methods shown in table of
Appendix A. As an example, with the French national
recommendation, reference intervals of 0"30 to 1"50
tkat 1-1 118
to 90 U 1- and 0"60 to 3"60 tkat 1- (36 to
216 U 1- were found for women (aged 10-45 years) and
men (aged 10-60 years), respectively [38].
The molar absorption coefficient, e, of NADPH (30 C,
339 nm) 630 m2 tool
-1 [61, 62].
The light path length, 1, is 0"01 m (= 10 ram).
Let the increase in absorbance per second at 339 nm be a,
-1
S
The total reaction volume, V, is 2"3 x 10-a 1.
The sample volume, v, is 0"1 10-a 1.
2"3 x 10-a
S
-1 i) b=a
630 x 0"01 x 0"1 x 10-a m2 mol-1 m
\ 0"630 ma //
a(3"651 tool s
-1 m-a)
a(3"651 kat m-3)
a(3651 [akat 1-1)
Note" Calculated for a measuring time of 60 s"
Let the increase in absorbance per 60 at 339 nm be A,
(60 s)
-1
b- A (3651 tmol (60 s)
-1 1-1)
A (3651 U/I).
12. Analytical variability
Data about inaccuracy are not available because no
international reference material has yet been established.
Preliminary data regarding imprecision appear in table 4
[8].
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Appendix A
Description ofpertinent factors in obtaining optimal
conditions for measurements
1. Introduction
Efforts to obtain standardized conditions for measuring
the catalytic concentration of creatine kinase have led to
the appearance of several national recommendations
within the last few years (see table A1). They are all
rooted in the same methodological principle. The basis
for the reaction conditions has been in the publications by
Szasz et al. during the last decade [8-14]. Re-examination
and confirmation of reaction conditions have also been
published in the late seventies by groups in North
America [15-22]. The Expert Panel on Enzymes ofIFCC
has followed these developments closely since 1976, when
a questionnaire among associate members of the Expert
Panel on Enzymes and individual clinical chemists made
clear that the IFCC should recommenda method based
on these same principles.
Accordingly, the Expert Panel on Enzymes, in close
collaboration with some of the members of the national
groups represented in table A1, and with members of the
working group on creatine kinase of the enzyme subcom-
mittee of the Committee ofStandards from the American
Association for Clinical Chemistry, have evaluated the
conditions of the national methods of table A1.
The following is a review of the various alternatives
considered in choosing the final conditions. In addition,
validation of the present IFCC method by response
surface methodology [23] is presented.
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Table A1. Comparison ofrecommendationsfor creatine kinase measurements by National Committees 1976-1982 with this IFCCproposal.
Scandinavian German Dutch Swiss British French
[1, 2] [3] [4] [5] [6] [7] IFCC
Temperature 37C
pH 6’5
Imidazole (mmol/1) 100
Mg2+ (as acetate) (mmol/1) 10
N-Acetyl-L-cysteine (mmol/1) 20
ADP (mmol/1) 2"0
p1,ps_Di adenosine-5 ’-)penta-
phosphate (mol/1) 10
AMP (mmol/1) 5
D-Glucose (mmol/1) 20
NADP+ (mmol/1) 2
EDTA (mmol/1) 2
Creatine phosphate (mmol/1) 30
Hexokinase (kU/1) ]" 3"5
Glucose-6-phosphateJ" dehydro-
genase (kU/1)
25C 30C 30(37C) 30C 30C 30C
6"7 6"7 6"6 6"6 6"6 6"6
100 100 100 100 100 100
10 10 10 10 10 10
20 20 20 20 20 20
2"0 2"0 2"0 2"0 2"0 2"0
10 10 10 10 10 10
5 5 5 5 5 5
20 20 20 20 20 20
2 2 2 2 2 2
2 2 2 2 2
o o o o o o
.5 .5 .0
(5 c) (0 c)
2.0 1.5
Volume fraction of sample 0"0435 0.0385
Preincubation (min) 5 3-5
Reaction initiated by creatine
phosphate + +
.5 .0 .0 .0
(5 c) (0 c)
0.0435 0.0333 0.0476 0.0333 0.0435
3-5 5 10 5 5
+ + + + +
(alternatively
serum)
Catalytic concentrations as stated in appropriate references.
3001 "--’-""o
2001
100 ]
6,0 6,5 7,0 7,5
pH
Figure A1. Dependence of apparent creatine kinase catalytic
concentration on pH (100 mmol/1 imidazole acetate buffer) at
o c [8}.
2. Buffer selection
2.1. pH
The dependence of creatine kinase activity on pH has
been determined by many investigators [1-8]. The
activity shows a maximum at pH 6"6, but the difference in
activity between pH 6"5 and 6"7 is only 2% (see figure A1,
[8]).
2.2. Buffer type
The selection ofan appropriate buffer for the reaction has
been considered by Szasz et al. [8] and Morin [15].
The majority of CK investigative work since 1975 has
been accomplished using imidazole as the buffer.
However, there has been some controversy surrounding
the choice of this buffer. Imidazole was difficult to obtain
in pure form, and decomposed during storage. This
problem has now been solved by the manufacturers and
much more stable and pure preparations are available
having low absorbance at the wavelength ofthe measure-
ment [2].
2,2-Bis(hydroxymethyl)-2,2’,2"-nitrilotriethanol (Bis-Tris),
due to its chelating ability and buffering capacity at the
pH of the assay, has been proposed as an alternate buffer
system to imidazole and EDTA [15]. However, studies by
Szasz et al. 13], by Nealon et al. [20], by the SCE [24] and
by the CK Study Group of the AACC [25] have shown
that there is no distinct superiority of this buffer over
imidazole with EDTA.
Studies relating recovery of catalytic concentration to the
ionic strength of the buffer show an inverse relationship
between catalytic concentration and buffer concentration
(see figure A2 and [13]). Buffer anions inhibit creatine
kinase. A buffer of 100 mmol/1 imidazole containing 2
mmol/1 EDTA is therefore a compromise concentration
between sufficient buffer capacity and minimal inhibition
[8].
3. Chelating substance, EDTA
Inclusion ofEDTA in the assay has several advantages: it
prevents autoxidation of N-acetyl-L-cysteine and the
formation of inhibitors from such oxidation [2, 13], the
stability of the CK reagent at 4C is increased from less
than 24 h to 5 days, and rates of conversion are increased
by reversal of the apparent inhibition of CK by en-
dogenous Ca2+ [18] and Fea+ [24]. Average increases of
apparentCK catalytic concentration in sera from healthy
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Figure A4. Effect of serum volume fraction on apparent creatine
kinase catalytic concentration [24].
Figure A2. Dependence of apparent creatine kinase catalytic
concentration on buffer concentration at 30C [13].
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Figure A3. EDTA influence on creatine kinase catalytic concen-
tration determined in serum, based on data presented in [7].
individuals and from patients with acute myocardial
infarction are from 1" to 1"2 times greater measured by
an assay at 30C containing EDTA, than in an assay,
also at 30 C, without added EDTA [7, 24] (see figure A3,
[7]).
4. Specimen
4.1. Type and volume fraction
Serum is the preferred specimen. Use of plasma contain-
ing heparin, EDTA, or citrate may give rise to unpre-
dictable rates of reactions [7, 24, 26].
The volume fraction of the sample is critical. Changes of
the volume fraction do not provide proportional changes
in the rate of conversion [1]. Therefore, the catalytic
concentrations of creatine kinase obtained with this
IFCC method are defined specifically at a volume
fraction of sample of 0"0435 (see figure A4, [2]).
4.2. Reactivation of catalytic activity by N-acetyl-L-cysteine
CK in serum is rapidly inactivated. Incubation with a
thiol having a high redox potential reactivates CK. This
thiol must fulfil several requirements, including rapid
and complete reactivation of CK catalytic activity, no
precipitation of proteins in the specimen, sufficient
solubility in solution and lack of obnoxious odour.
Employing freeze drying for incorporation into lyophi-
lized reagent kits is not an absolute requirement for an
IFCC method but it is convenient for routine methods
[]5, 5].
Glutathione was rejected as a reactivator because reacti-
vation is incomplete and requires a longer time. in
addition, glutathione reductase in serum causes de-
creased rates of conversion.
N-acetyl-L-cysteine has been found to be satisfactory. At
a volume fraction ofsample of0"0435 and with 20 mmol/1
of N-acetyl-L-cysteine in the CK reagent, reactivation of
CK catalytic activity in serum samples stored for one
week at 4C is 99% complete [1, 7, 8]. In addition,
N-acetyl-L-cysteine does not cause microprecipitation of
sample proteins [1] and is easily soluble at pHs between
6"5 and 6"7 at the required concentration.
Thiols in solution undergo irreversible oxidation. This
has two effects: loss of available sulphhydryl groups [12,
16], and formation ofpotent CK inhibitors [13, 24]. Both
processes are accelerated by certain polyvalent cations,
and, therefore, are retarded by the presence of chelators.
Inclusion of EDTA stabilizes N-acetyl-L-cysteine in the
reagent for 24 h at room temperature and 5 days at 4C
[2, 13, 24] (see figure A5 and [2]). N-acetyl-L-cysteine
must be of the highest purity to avoid preformed
inhibitors [7].
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2 3 4 5 6 7 Figure A7. Dependence of apparent creatine kinase catalytic
concentration on ADP concentration [8].
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Figure A5. Stability of CK reagents at 4C [24].
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Figure A6. Reactions involved in the catalytic mechanism of
creatine kinase [27].
5. The catalysed reaction
5.1. Catalytic mechanisms
The true substrates ofthe enzyme should be considered as
the magnesium-nucleotide complex, which for this
method is Mg-ADP, and free creatine phosphate. The
enzyme appears to possess two binding sites on each
subunit, one for the nucleotide and one for the guanidino
substrate. The site for nucleotide binding presumably
involves an arginine group and a lysyl group. It is
speculated that a histidyl residue is involved in the
guanidino site. Figure A6 has been adopted from Watts
[27] and shows the rate equation leading to the formation
of the transition complex, and the dissociation of the
transition complex into products. It is thought that the
process is a rapid equilibrium, random bimolecular
mechanism in which either the nucleotide or the guani-
dino substrate may bind first [27].
Because the nucleotide binds to the active site as the
magnesium ion complex, magnesium ion concentration is
important in establishing the equilibrium concentration
ofcomplexed nucleotide. Wevers et al. [28] estimated that
the effective equilibrium concentrations ofMg-ADP and
creatine phosphate were 1.’61 mmol/1 and 25"8 mmol/1,
respectively, at the nominal reaction conditions.
Small anions can occupy the site normally filled by the
gamma-phosphoryl group of magnesium-ATP to form a
dead-end complex, which resembles the transition state
of the normal enzyme substrate complex. This explains
the inhibitory effects of small anions such as nitrate,
sulphate, and chloride [27, 29].
5.2. Substrate concentrations
Although the true substrates are Mg-ADP and free
creatine phosphate, for the sake of practicality total
concentrations are given forADP and creatine phosphate
in the following paragraphs. This convenience is war-
ranted because the influence ofimidazole, EDTA, AMP,
and other reagent components on the concentration ofthe
respective substrates is unknown.
5.2.1. ADP and magnesium
Univariate increase ofADP shows a broad plateau with
no increase of reaction rates beyond 2 mmol/1 [1, 8] (see
figure A7, [8]).
Multivariate studies show that simultaneous increases of
Mg2+ to 15 mmol/1 and ADP to 3"5 mmol/1 increase CK
reaction rates by 6-8% [25, 30, 31] (see Section 8). This
change increases the ADP/AMP molar ratio from the
current 0"4 to 0"7, and will increase residual adenylate
kinase activity [9]. Magnesium is necessary for both
creatine kinase and hexokinase activity. The inter-
relationship between the chelating agents and the sub-
strates, particularly ADP and magnesium and calcium
and other divalent cations endogenously present in the
sample, is not known at the molecular level. However, the
effects ofeach ofthese on the rate ofconversion have been
described [1, 2, 8, 13, 18]. Therefore, magnesium has
been selected at a concentration of 10 mmol/1 with an
EDTA concentration of2 mmol/1. Km values forADP are
shown in table A2.
5.2.2. Creatine phosphate
The Km values of creatine phosphate for creatine kinase
in serum are shown in table A2. Most studies report
maximal activity at a broad plateau between 20 mmol/1
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Table A2. Michaelis constants for total ADP and creatine
phosphate at 30 C.
Km (creatine
Form of Ck Km (ADP) phosphate)
MM1 0"21 2"13
MM2 0"24 2"87 [28]
MM3 0"28 3"47
MB 0"17 1"2 [11]
BB 0’13 0"9
Macro CK type 0"07 1’67 [32] Macro CK type 2 0.06 0"45
400- s-’ .......
"""’’-o 30C
300
200.
O’
0 25 50 75 100
Croatino phosphate (mmol/litro)
Figure A8. Dependence of apparent creatine kinase catalytic
concentration on creatine phosphate concentration [8].
and 40 mmol/1.30 mmol/1 has been selected as optimal in
both univariate [1, 7 11] (see figure AS, [8]) and
multivariate studies [25, 30, 31] (see also Section 8).
6. Competitive reaction: interference by adenylate
kinase
Adenylate kinase (EC 2.7.4.3, AK) Catalyses the re-
versible conversion ofADP to ATP and AMP:
AK 2 ADP >ATP + AMP
Adenylate kinase, also known as myokinase, is a remark-
ably stable enzyme and is present in the same tissues as
creatine kinase. Conditions favouring the increased
activity of CK also favour the increased activity of
adenylate kinase. The pH optima for both enzymes are
within two pH units ofeach other. The overall measured
reaction rate includes catalytic activity attributable to
adenylate kinase. Consequently, corrections must be
made. This is accomplished by including inhibitors of
adenylate kinase in the reaction mixture, and, in
addition, compensation for a sample blank rate due to the
residual adenylate kinase catalytic activity.
Adenylate kinase may be inhibited by various substances,
including AMP [1, 9, 10], P1,ps-Di(adenosine-5’-
pentaphosphate [9, 10, 33, 36] and sodium fluoride
[10, 34, 37].
Maximal inhibition of adenylate kinase by AMP was
found when the AMP/ADP ratio was 10:1 [1, 9, 10].
However, AMP also inhibits creatine kinase [1, 9]. CK
inhibition is proportional to the concentration of AMP
[31 although the degree ofinhibition varies among sera.
AMP inhibits adenylate kinase by a mechanism which is
thought to involve the formation ofa ’dead end’ complex,
either AMP-enzyme-AMP or ADP-enzyme-AMP [35].
Inhibition of adenylate kinase increases as AMP concen-
tration increases and approximately 7% adenylate kinase
catalytic activity remains at a concentration of 10 retool/1
of AMP. Because of the competitive nature of the
inhibition, the adenylate kinase inhibition also depends
on theADP concentration. Inhibition ofCK byAMP also
depends on the AMP/ADP ratio [9, 10]. At a ratio of 5,
CK is inhibited by approximately 10%. At a ratio of 2"5,
CK is inhibited between 5 and 8%. Because both CK and
adenylate kinase are sensitive to the AMP/ADP ratio, its
value must be selected so that CK is minimally inhibited
and adenylate kinase blanks are acceptably low. At an
AMP/ADP ratio of 2"5, sample blank rates are decreased
significantly, but the highest values of residual adenylate
kinase amounted to 20% of the upper limit of the
reference range for creatine kinase catalytic activity 10].
The dilemma of reducing residual adenylate kinase
without concomitantly inhibiting CK is reduced by
adding a second inhibitor.
Diadenosine polyphosphates have been examined as
inhibitors of adenylate kinase. The compound with
greatest inhibitory capability is P1,p5-Di(adenosine-5’-)-
pentaphosphate [36], a potent inhibitor of erythrocyte,
muscle, and purified liver adenylate kinase. The penta-
phosphate does not inhibit platelet adenylate kinase
nearly as well. A combination of AMP and
P1,ps-Di(adenosine-5’-)pentaphosphate has been recom-
mended by Szasz et al. 10] at concentrations of5 mmol/1
and 10 tmol/1, respectively. This results in inhibition of
adenylate kinase from erythrocytes and muscle by 97%,
from liver by 95% [33] and from platelets by 90% [10].
Fluoride is a non-competitive, adenylate kinase inhibitor
with a Ki at 25 C of 2"5 mmol/1 [10]. Neither singly,
nor in combination with AMP or with p1,p5_
Di(adenosine-5’-)pentaphosphate 10] does fluoride offer
any advantage over the selected AMP and
P1,ps-Di(adenosine-5’-)pentaphosphate inhibitor combi-
nation [9, 10]. Fluoride has two disadvantages: it causes
turbidity in the reagent due to precipitation of mag-
nesium fluoride, and the lag-time before achieving
maximum inhibition by fluoride is 6 rain at 30C [10].
There are conflicting data regarding inhibition ofCK by
sodium fluoride; 8% inhibition at 25 mmol/1 [10], no
inhibition at 25 mmol/1 [34], and less than 3% when used
in combination with AMP at 6 mmol/1 and 2 mmol/1,
respectively [37].
The inhibition potentials of the various components are
summarized in table A3.
Adenylate kinase catalytic activity not completely in-
5 hibited by AMP and p1,p-Di(adenosine-5-)penta-
phosphate is measured separately by the sample blank
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Table A3. Fractional residual adenylate kinase catalytic activity in the reagent mixturefor measurement ofcreatine kinase with different
inhibitors included. Modifiedfrom references (1, 7, 9, 10, 33).
Source of adenylate kinase
Inhibitor Liver]" Liver+ + Erythrocytes Thrombocytes Muscle
AMP 5 mmol/1
P1,p5-Di(adenosine-5’-)pentaphosphate 10 btmol/1
AMP 5 mmol/1 ]
P1,p5-Di(adenosine-5’-)pentaphosphate 10 btmol/1
NaF 25 mmol/1
NaF 25 mmol/1 [
AMP 5 mmol/1
NaF 25 mmol/1
P,p5-Di(adenosine-5’-) pentaphosphate. 10. btmol/1
0’20
0"08
0.06
"
Liver preparation obtained from Blue Sepharose column [33].
++ Liver extract clarified by centrifugation [33].
0"50 0"10 0"20 0"10
0"50 0"03 0’20 0"03
0"05 0"03 0" 10 0"01
0"10 0"10 0’15 0"10
0"05 0"02 0"02
0"05 0"01 0"01
rate ofconversion, in which creatine phosphate is omitted
from the reaction mixture.
In samples from healthy persons this blank rate is zero or
very low. In samples from patients with liver and heart
diseases, residual adenylate kinase catalytic activity is
significant [38]. In addition, in a reference method any
possible side-reaction that may contribute to nonspecifi-
city of the method should be compensated for. Therefore,
measurement of the sample blank reaction is part of the
IFCC method for creatine kinase.
It has been established [39] that creatine phosphate at
concentrations from 10 to 90 mmol/1 does not inhibit
human adenylate kinase from erythrocytes, liver or
skeletal muscle.
7. Auxiliary and indicator reactions
7.1. Hexokinase (A TP: D-hexose-6-phosphotransferase, EC
2.7.1.1). Glucose-6-phosphate dehydrogenase (Glucose-6-
phosphate: NADP+ 1-oxidoreductase, EC 1.1.1.49)
Hexokinase from baker’s yeast is used as the auxiliary
enzyme coupling the primary reaction to the indicator
reaction. Both the form in which the enzyme is obtained
and its final concentration (activity) in the reaction
mixture influence the apparent CK activity that is
measured. Because of the influence of small anions such
as sulphate, nitrate, and chloride on the activity of
creatine kinase in the formation of the ’dead end’
transition complex (see below), ammonium sulphate
suspensions of the auxiliary and indicator enzymes
should be avoided. The catalytic concentration of hexo-
kinase influences the duration of the lag phase of the
reaction. At hexokinase catalytic concentrations lower
than 50 btkat/1 (measured at 30C in theCK reagent), the
lag phase is greater than 120 s (see figure A9, [8]).
The indicator enzyme is glucose-6-phosphate dehydro-
genase. Two types of this enzyme are commonly used for
analytical purposes: one from yeast, the other from
Leuconostoc mesenteroides. The coenzyme specificities of the
enzymes from these sources are different. The yeast
enzyme is specific for NADP+ while the enzyme for L.
,. ,,,,.
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Figure A9. Lag phase as a function of hexokinase catalytic
concentration (U/ml at 250C) in an assay mixture containing
glucose-6-phosphate dehydrogenase (2 U/ml at 25C) [8].
mesenteroides is able to use either NADP+ or NAD+.
Because most dehydrogenases present in human sera
have specificity for NAD+ and NADH, sera having
elevated levels of lactate dehydrogenase may show
different CK catalytic concentration when NAD+ is used
instead of NADP+. Metabolites capable of acting as
substrates for dehydrogenases in the presence ofNADH
could drive the indicator reaction in the reverse direction
and reduce the apparent initial rate ofconversion. Results
obtained using reagents that included NADP+ and
glucose-6-phosphate dehydrogenase from either source
were comparable [14]. A reagent formulated to contain
glucose-6-phosphate dehydrogenase from the Leuconostoc
species and NAD+ yielded results that were approxi-
mately6% lower than those obtained usingNADP+ 14].
A-combination ofhexokinase at 50 btkat/1 (3000 U/I) and
glucose-6-phosphate dehydrogenase at 33 btkat/1 (2000
U/l) has been chosen. This is not rate limiting in the
measurement of the creatine kinase catalytic concen-
tration below about 40 btkat/1 and it ensures a lag phase of
less than 120 s (see figure A10, [8]). Under these
conditions, the reagent blank rate of conversion will
correspond to less than 0.04 btkat/1, provided the reagent
specifications described in Appendix B are fulfilled.
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Figure A10. Lag phase as a function of glucose-6-phosphate
dehydrogenase catalytic concentration (U/ml at 25C) in an assay
mixture containing hexokinase (2 U/ml at 25C) [8].
120 to 180 s after the start will be linear with a catalytic
concentration ofCK up to at least 40 tkat/1 (2400 U/l) [7,
8].
8. Evaluation ofthe selected conditions by multivar-
iate analysis
The IFCC conditions for the measurement ofCK have
also been confirmed by multivariate analysis and by
response surface analysis. This technique requires simul-
taneous variation of component concentrations with
subsequent computer analysis of the responses obtained
at the defined reaction conditions. Results of the
computer analysis may be displayed in multidimensional
space (usually two dimensions) by plotting the concen-
tration of one variable versus the concentration of a
second variable and visualizing the response in terms of
iso-response contours. Reaction conditions are inter-
preted by plateaus, peaks, or valleys in the topography of
the response surface [23]. These experiments have been
performed by members of the study group for CK of
AACC [25, 30, 31].
25O
200
, 150 ._
o 100
50
0 20 4’0 6’0 8’0 1(;0
Glucose (mmol/litre)
Figure All. Effect ofglucose concentration on apparent creatine
kinase catalytic concentrations [8].
7.2. D-Glucose
Rates of conversion are independent of the glucose
concentration in the range of 10 mmol/l to 100 mmol/1.20
mmol/1 provides full catalytic activity with no side-
reactions [1, 7, 8] (see figure A11, [8]).
7.3. NADP+
The proportionality between CK catalytic concentration
and the rate of conversion also depends on the NADPH
+H+/NADP+ molar ratio. NADPH is a competitive
inhibitor of glucose-6-phosphate dehydrogenase [8]. An
initial concentration ofNADP+ of 2 mmol/1, i.e. about 20
times the average Km of glucose-6-phosphate dehydro-
genase for NADP+ at 37 C, will sustain a constant rate
until NADPH formation has increased the NADPH
+H+/NADP+ molar ratio to about 10. At a volume
fraction ofsample of0"0435 this corresponds tosustaining
a.constant rate of conversion for apparent CK catalytic
concentration of 10 btkat/1 for 10 min. Rates monitored
Reaction surfaces were examined around five variables
(imidazole, ADP, creatine phosphate, magnesium, and
pH) in the ’Scandinavian’ method of table A1 for
determining creatine kinase catalytic concentration [30].
Factorial experimentation (five level, five factor) was
conducted at reaction temperatures of 30 and 37 C.
Theoretical response surfaces were computed by fitting a
quadratic polynomial equation to the experimental data
by least-squares regression. Essentially no differences
were apparent in the theoretical curves among five
human serum specimens analysed at each reaction
temperature.
Plots (see figure A12, [30]) of the response-surface data
showed the following: for pH and imidazole, maximal
catalytic concentration was obtained in the region of the
proposed IFCC conditions; the response to changes in
creatine phosphate concentration was investigated in
respect to changes in concentration ofADP, magnesium
acetate and hydrogen ion. A relatively broad plateau of
catalytic concentration was observed over the concen-
trations of the studied variables.
The apparent maxima lie close to the conditions given in
this document. For magnesium and ADP, creatine kinase
catalytic concentration recovery follows a gently increas-
ing contour as the concentrations of both ADP and
magnesium are increased.
Maximal creatine kinase catalytic concentration
occurred at magnesium, 15 mmol/1, and ADP 3"5 mmol/1,
concentrations greater than those selected in the IFCC
method. Full details of these studies have been published
by Sampson et al. [30, 31].
Optimal concentrations of magnesium and ADP are
interdependent 15, 40]. Two effects from increasing total
ADP and total magnesium concentrations to 3"5 mmol/1
and 15 mmol/1 at 30 C, respectively [30], can be found:
(a) an increase in the creatine kinase catalysed rate of
35IFCC The measurement of the catalytic concentration of creatine kinase
:"’N l"’k/IIII
CREATEATE (m/L) (I/L) ADP (L)
Figure A12. Optimization (pH, imidazole creatine phosphate,
ADP, and magnesium acetate concentration for a human serum
using computerized Response Suace Methodolo (RSM). The
pool was prepared by combining specimens having apparent
CK-MB relative catatic concentrations between 10 and 22%.
All other reaction conditions are the same as in this recommended
method, except ADP, creatine phosphate and magnesium acetate
concentrations which were varied [30].
conversion of5-8%; and (b) an increase in the nonspecific
rate of conversion catalysed by adenylate kinase.
Therefore, the Expert Panel on Enzymes had to consider
if these small changes should be included in an IFCC
method. This would be necessary if a new method
significantly improves accuracy, precision, or both. In the
absence of primary reference methods for assay of
enzymes, accuracy may be considered to be proportional
to recovered catalytic concentration. That is to say that
methods which result in higher catalytic concentrations
for a reference specimen are considered more accurate.
The investment in time and manpower required to
validate a new method not only for accuracy but also for
transferability, precision, and expected reference values,
is substantial. The decision not to replace well-accepted
conditions as described in this IFCC method [1-8] by
slightly changed conditions [30, 31] was therefore made
by the Expert Panel on Enzymes. This decision was based
on the above criteria and was carefully considered. The
5% to 8% activity increase resulting from the change in
total ADP and total magnesium concentrations was felt
not to have significant importance to.justify a change.
Additionally, no improvement in precision was
demonstrated.
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Appendix B
Reagent Specifications: Conditions for Measuring
the Catalytic Concentration of Auxiliary and
Indicator Enzymes and their Contaminants
In the IFCC Method for CK, the auxiliary enzyme is
hexokinase (ATP: D-hexose-6-phosphotransferase, EC
2.7.1.1, HK) and the indicator enzyme is glucose-6-
phosphate dehydrogenase (D-glucose-6-phosphate:
NADP+ 1-oxidoreductase, EC 1.1.1.49, G-6-P DH). The
conditions for measurement of the catalytic concen-
trations of these two enzymes (temperature, pH, reagent
concentrations) correspond to those ofthis IFCC creatine
kinase method.
Both enzymes must be as free as possible from contami-
nating enzymes, including CK and adenylate kinase,
which will cause a significant reagent blank rate. Traces
of 6-phosphogluconate dehydrogenase (6-Phospho-D-
gluconate: NADP+ 2-oxidoreductase (decarboxylating),
EC 1.1.1.44) will falsely increase the apparent CK rate
due to the production of an additional molecule of
NADPH + H+ for each molecule of D-glucono-
6-1actone-6-phosphate produced in the indicator
reaction.
Hexokinase and glucose-6-phosphate dehydrogenase
must be supplied in glycerol, or lyophilized. Standard
enzyme suspensions in (NH4)2SO4 cause a loss of about
10% in reaction rates [1 ].
Measurement of glucose-6-phosphate dehydroge-
nase catalytic concentration in stock solution
Principle
As an example, let the unknown catalytic concentration
of glucose-6-phosphate dehydrogenase in the stock solu-
tion of enzyme be about 4 mkat/1 (240 kU/1 30 C, this
method), This catalytic concentration has to be diluted
about 10 000 fold in working solution VI in order to be
measured.
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Table B1. Analytical system for measurement of
D-glucose-6-phosphate dehydrogenase [EC 1.1.1.49] catalytic
activity concentration.
Pipette
into
cuvettes" Volume
Substance concentration in
final, complete mixture
Solution
VII 2"00 ml
Water
Imidazole
EDTA
Mg2+
ADP
AMP
P1,ps-Di(adenosine-5’-)-
pentaphosphate
N-Acetyl-L-cysteine
D-Glucose
NADP+
Glucose-6-phosphate de-
hydrogenase
0" 100 ml Volume fraction
100 mmol/1
2 mmol/1
10 mmol/1
2 mmol/1
5 mmol/l
10 tmol/1
20 mmol/l
20 mmol/l
2 mmol/1
Approxi-
mately
0"4 kat/1
0"0435
(1:)
Mix carefully. Incubate the reaction mixture at 30C and wait a
minimum of 300 for temperature equilibration.
Solution
IX 0"200 ml D-Glucose-6-phosphate 10 mmol/1
Mix again and incubate for 120 s. Monitor the increase in
absorbance under steady state conditions at 339 nm for at least
60 s.
(VI) Working solution of buffer-reagent mixture
(working solution III prepared without enzymes,
pH 6"6 [30 C]) (see Section 7).
(VII) Dilution of glucose-6-phosphate dehydrogenase,
step 1. Pipette 2"00 ml of solution VI into a glass
tube. Add 20 btl of the unknown glucose-6-
phosphate dehydrogenase stock solution. Mix
well.
(VIII) Dilution of glucose-6-phosphate dehydrogenase,
step 2. Pipette 2"00 ml of solution VI into a glass
tube. Add 20 1 of solution VII. Mix well.
(IX) Initiating reagent (D-glucose-6-phosphate, 115
mmol/1). Dissolve 324 mg of D-glucose-
6-phosphate, monosodium salt (C6H12OgPNa,
Mr 282"2) in 5 ml of solution I. Dilute to 10 ml
with water. The final concentration of
D-glucose-6-phosphate in the assay mixture will
be 10 mmol/1.
Conditions for measurement
The conditions for measurement for glucose-6-phosphate
dehydrogenase catalytic concentration are similar to
those of the IFCC creatine kinase method, except that
hexokinase and creatine phosphate are omitted.
Glucose-6-phosphate dehydrogenase is present at a rate
limiting catalytic concentration. The reaction is initiated
with D-glucose-6-phosphate (see table B1).
Calculation
The catalytic concentration, b, of glucose-6-phosphate
dehydrogenase in the stock solution is calculated as
follows:
The molar absorption coefficient, e, of NADPH (30 C,
339 nm) is 630 m2 mo1-1 [2, 3].
The light path length, 1, is 0"01 m (= 10 mm).
Let the increase in absorbance per second at 339 nm be a
The total reaction volume, V, is 2"3 x 10-a 1.
The ’sample’ volume, v, is 2 x 10-a 1.
The dilution factor, , of glucose-6-phosphate dehydro-
genaseis 101 x 101 10201.
2.3 x 10-a x 10201 s
-1
b= a
630x0"01 x 2 x 10-ammo1-1
23 462 mol s- 1)
a
12"6 m
a(1862 mol m
a(1862 kat m-a)
a(1862 x 10a [akat 1-1).
ml)
Note" Calculated for a measuring time of 60 s:
Let the increase in absorbance per 60 s at 339 nm
be A (60 s) -1.
b A(1862 x 10a lamol (60 s)
-1 1-1
A(1862 x 10a U/l).
Example" Let the increase in absorbance at 339 nm
0"130 (60 s) -1.
b 242 kU/1 (= 4"034 mkat/1).
Measurement of hexokinase catalytic concentration
in stock solution
Principle
As an example, let the unknown catalytic concentration
of hexokinase in the stock solution of enzyme be about 4
mkat/1 (240 kU/1 30C, this method). This catalytic
concentration has to be diluted about 10 000 fold in
working solution X in order to be measured.
(X) Working solution ofbuffer-reagent-enzyme mix-
ture (working solution III prepared without
hexokinase, pH 6"6 [30 C]) (see Section 7).
(XI) Dilution of hexokinase, step 1. Pipette 2"00 ml of
solution X into a glass tube. Add 20 lzl of the
unknown hexokinase stock solution. Mix well.
(XII) Dilution ofhexokinase, step 2. Pipette 2"00 ml of
solution X into a glass tube. Add 20 btl ofsolution
XI. Mix well.
(XIII) Initiating reagent (adenosine-5’-triphosphate
[ATP], 115 mmol/1. Dissolve 696 mg of
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Table B2. Analytical system for measurement of hexokinase
catalytic concentration.
Pipette Substance or catalytic
into concentration in final,
cuvettes: Volume complete mixture
Solution
XII 2.00 ml
Water
Imidazole
EDTA
Mg2+
ADp
AMP
P1,ps-Di(adenosine-5-)-
pentaphosphate
N-Acetyl-L-cysteine
D-Glucose
NADP+
Hexokinase
Glucose-6-ptiosphate de-
hydrogenase (2000 U/I)
0" 100 ml Volume fraction
100 mmol/1
2 mmol/1
10 mmol/1
2 mmol/1
5 mmol/1
10 tmol/1
20 mmol/1
20 mmol/1
2 mmol/1
Approxi-
mately
0"4 btkat/1
33 kat/1
0"0435
( ")
Mix carefully. Incubate the reaction mixture at 30C and wait a
minimum of 300 s for temperature equilibration.
Solution
XIII 0"200 ml Adenosine-5’-triphosphate 10 mmol/1
Mix again and incubate for 120 s. Monitor the increase in
absorbance under steady state conditions at 339 nm for 60 s.
adenosine-5’-triphosphate, disodium salt
(C10H14N5013P3Na2"3H20, in 5 ml of solution I
(see Section 7). Dilute to 10 ml with water. The
final concentration of adenosine-5’-triphosphate
(ATP) in the assay mixture will be 10 mmol/1.
Freshly prepared solution XIII must be used.
Conditionsfor measurement
The conditions for measurement of hexokinase catalytic
concentration are similar to those of the IFCC creatine
kinase method, except that creatine phosphate is omitted.
Hexokinase is present at a rate limiting catalytic concen-
tration. The reaction is initiated with adenosine-5’-
triphoshpate (ATP) (see table B2).
Calculation
The catalytic concentration, b, ofhexokinase in the stock
solution is calculated as follows:
The molar absorption coefficient, e, of NADPH (30 C,
339 nm) is 630 m2 tool
-1 [2, 3].
The light path length, 1, is 0"01 m (= 10 ram).
Let the increase in absorbance at 339 nm be a (s-l).
The total reaction volume, V, is 2"3 x 10
-3 1.
The ’sample’ volume, v, is 2 x 10
-3 1.
The dilution factor, , of hexokinase is 101 x 101 10
201.
2.3 x 10
.3 x 10201 s
-1 ) b a 630 x 0.01 x 2 x 10
.3 m2 mol-1 m
a(2346212"6mlm3s-1.)
a(1862 mol m
-3 s-1)
a(1862 kat m-3)
a(1862 x 103 tkat 1-1).
Note" Calculated for a measuring time of 60 s:
Let the increase in absorbance per 60 s at 339 nm
be A, (60 s)-.
b A(1862 x 103 bmol (60 s)
-1 1-1)
A(1862 x 103 U/l).
Example: Let the increase in absorbance at 339 nm
0"130 (60 s)
-1
b 242 kU/1 (= 4034 mkat/1).
Measurement of contaminating 6-phospho-D-
gluconate: NADP+2-oxidoreductase (decarboxylat-
ing), [EC 1.1.1.44] in the IFCC assay for creatine
kinase
The presence of 6-phospho-D-gluconate dehydrogenase
will cause a reagent blank rate due to NADPH’H+
production by the following reaction [4]:
6-phospho-D-gluconate + NADP+
6-phospho-D-gluconate dehydrogenase
[EC. 1.1.1.44]
ribulose-5-phosphate + CO + NADPH’H+.
The conditions for measurement of 6-phospho-D-
gluconate dehydrogenase catalytic activity concentration
are similar to thoe of the IFCC creatine kinase method,
except that creatine phosphate is omitted. The reaction is
initiated with 6-phospho-D-gluconate.
(XIV) Initiating reagent (6-phospho-D-gluconate, 23
mmol/1). Dissolve 87 mg of 6-phospho-D-
gluconate, trisodium salt (C6H1000PNa3"2HO,
Mr 378" 1) in 5 ml of solution I. Fill up to 10 ml
with water. The final concentration of6-phospho-
D-gluconate in the assay mixture will be 2
mmol/1.
Conditions for detection of 6-phospho-D-gluconate" NADP+ 2-
oxidoreductase (decarboxylating)
The conditions for detection of 6-phospho-D-gluconate:
NADP+ 2-oxidoreductase catalytic concentration are
similar to those of the IFCC creatine kinase method,
except that creatine phosphate is omitted. The reaction is
initiated with 6-phospho-D-gluconate. The concentration
of 6-phospho-D-gluconate corresponds to that which
theoretically might arise from conversion ofall NADP+ in
the assay mixture. This concentration does not
necessarily support a linear rate of conversion, but will
detect any significant interference from contaminating
6-phospho-D-gluconate dehydrogenase (see table B3).
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Table B3. Analytical system for the detection of 6-phospho-D-
gluconate: NADP 2-oxidoreductase (decarboxylating) [EC
1.1.1.44].
Pipette Substance or catalytic
into concentration in final,
cuvettes: Volume complete mixture
Solution
III
Water
2’00 ml Imidazole
EDTA
Mg2+
ADP
AMP
p1,p5_Di adenosine-5 ’-)-
pentaphosphate
N-Acetyl-L-cysteine
D-Glucose
NADP+
Hexokinase (3000 U/l)
Glucose=6-phosphate de-
hydrogenase (2000 U/l)
0’100 ml Volume fraction
100 mmol/1
2 mmol/1
10 mmol/1
2 mmol/1
5 mmol/1
10 tmol/1
20 mmol/1
20 mmol/1
2 mmol/1
50 tkat/1
33 kat/1
0.0435
(1:23)
Mix carefully. Incubate the reaction mixture at 30C and wait a
minimum of 300 for temperature equilibration.
Solution
XIV 0.200 ml 6-Phospho-D-gluconate 2 mmol/1
Mix again and incubate for 120 s. Monitor the increase of
absorbance at 339 nm for at least 60 s.
Evaluation
Ifthe increase ofabsorbance at 339 nm exceeds 0"001 per
60 s, this may be due to the presence of contaminating 6-
phospho-D-gluconate dehydrogenase in either the hexo-
kinase or in the glucose-6-phosphate dehydrogenase stock
solution. Consequently, the enzyme preparation in
question must be replaced.
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